Antidepressants and traffic safety
Depression is a common disease that is often pharmaceutically treated with tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Both groups of drugs have proven to be effective in treating depressive symptoms, however they differ in adverse effect profile. This chapter discusses their effects on driving ability. On the road driving tests have shown that TCAs such as imipramine, doxepine and amitriptilyne significantly impair driving performance after single dose administration. However, after one to two weeks of daily treatment tolerance developed and no significant driving impairment was reported. Sedative antidepressants such as mianserin and mitrazapine administered at bedtime produce significant driving impairment the morning following single dose administration and after one week of daily treatment. In contrast, SSRIs such as fluoxetine and paroxetine had no significant effects on driving ability. Also, venlafaxine did not affect driving performance. The chapter concludes by discussing that untreated depression impairs driving ability and that reported somnolence correlates significantly with reduced driving performance.
KeywordsSingle Dose Administration KDYH EHHQ WKDQ WKDW
Unable to display preview. Download preview PDF.
- 1.Louwerens JW, Brookhuis KA, O’Hanlon JF (1984) The effects of antidepressants oxaprotiline, mianserin, amitriptyline and doxepin upon actual driving performance. Groningen, The Netherlands. Traffic research Center, technical report.Google Scholar
- 2.Schoenmakers EAJM, Robbe HWJ, O’Hanlon JF (1989) Acute and subchronic effects of the antidepressants levoprotiline and doxepin on the performance of healthy volunteers in psychometric and actual driving tests. Maastricht, The Netherlands. University of Maastricht, Institute for Human Psychopharmacology, technical report.Google Scholar
- 3.Ramaekers JG, van Veggel LM, O’Hanlon JF (1994) A cross-study comparison of the effects of moclobemide and brofaromide on actual driving performance and estimated sleep. Clin Neuropsychopharmacol 17(suppl 1): S9–S18.Google Scholar
- 9.Ramaekers JG, Muntjewerff ND, van Veggel LMA et al. (1998) Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol Clin Exp 13(suppl 2): S7–S97.Google Scholar